Avant Changes Name to Celldex Therapeutics, Hires Marucci as Permanent CEO

Xconomy Boston — 

Avant Immunotherapeutics said today it is changing its name to Celldex Therapeutics as part of the merger the two companies announced in the first quarter. The Needham, MA-based company (NASDAQ: AVAN) will change its ticker symbol to (NASDAQ: CLDX), starting Oct. 1. The company’s board also announced that Anthony Marucci, who has worked as interim CEO since May, has gotten the job on a permanent basis. Celldex is developing antibody drugs to deliver vaccines directly to their therapeutic targets.